|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-8-25
|
|
pubmed:abstractText |
The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naïve patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoxazines,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclohexanes,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Fusion Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, CCR5,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine,
http://linkedlifedata.com/resource/pubmed/chemical/efavirenz,
http://linkedlifedata.com/resource/pubmed/chemical/maraviroc
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-4336
|
|
pubmed:author |
pubmed-author:BurnsideRobertR,
pubmed-author:CraigCharlesC,
pubmed-author:Di PerriGiovanniG,
pubmed-author:FrankIanI,
pubmed-author:GoodrichJamesJ,
pubmed-author:HeeraJayvantJ,
pubmed-author:MayerHowardH,
pubmed-author:McCrackenJenniferJ,
pubmed-author:PontaniDennisD,
pubmed-author:SaagMichaelM,
pubmed-author:Sierra-MaderoJuanJ,
pubmed-author:WoodRobinR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
125-32
|
|
pubmed:meshHeading |
pubmed-meshheading:20736149-Adolescent,
pubmed-meshheading:20736149-Adult,
pubmed-meshheading:20736149-Aged,
pubmed-meshheading:20736149-Anti-HIV Agents,
pubmed-meshheading:20736149-Benzoxazines,
pubmed-meshheading:20736149-Cyclohexanes,
pubmed-meshheading:20736149-Drug Therapy, Combination,
pubmed-meshheading:20736149-Female,
pubmed-meshheading:20736149-HIV Fusion Inhibitors,
pubmed-meshheading:20736149-HIV Infections,
pubmed-meshheading:20736149-HIV-1,
pubmed-meshheading:20736149-Humans,
pubmed-meshheading:20736149-Lamivudine,
pubmed-meshheading:20736149-Male,
pubmed-meshheading:20736149-Middle Aged,
pubmed-meshheading:20736149-Receptors, CCR5,
pubmed-meshheading:20736149-Treatment Outcome,
pubmed-meshheading:20736149-Triazoles,
pubmed-meshheading:20736149-Zidovudine
|
|
pubmed:articleTitle |
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
|
|
pubmed:affiliation |
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CIFBIOTEC Medica Sur, Tlalpan, Mexico.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
